title: Managed care aspects of psoriasis and psoriatic arthritis.
abstract: The chronic and systemic nature of psoriasis has a significant impact on direct costs, indirect costs, and patient quality of life. Psoriasis is associated with comorbid conditions that add to the burden of the disease, especially in moderate to severe disease. The total estimated annual healthcare burden of psoriasis may be as high as $35.2 billion, with $12.2 billion in direct costs and $23 billion in indirect costs (attributed to reduced health-related quality of life and lost productivity). These costs vary based on the severity of the disease; pharmacy costs account for the majority of the burden, especially in severe disease. Biologic therapies are largely responsible for the pharmacy costs. Approval of biosimilar products in the near future may ease some of this burden for payers and patients, although new agents have also been recently approved, with more in the pipeline. The healthcare costs of psoriasis management substantially increase with comorbid conditions, such as heart disease, hyperlipidemia, hypertension, diabetes, and lung disease. These comorbidities also include psychiatric conditions, such as social stigmatization, depression, and suicide. The overall costs associated with comorbidities are estimated to be an additional $22,713 per patient per year. Appropriate treatment selection and timing may curtail the progression of psoriasis, and, as a result, can decrease the economic burden. As treatment options vary based on comorbidities, long-term remission goals, and medication costs, conducting a comprehensive patient assessment is imperative. Drug utilization reviews steered by specialty pharmacists may help reduce costs and improve outcomes by providing treatment monitoring and patient education.
authors.affiliation: drevans@evans-dermatology.com.
authors.forename: Colby
authors.initials: C
authors.lastname: Evans
mesh_terms: D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000191:economics / Q000628:therapy; D001685:Biological Factors / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D005260:Female; D017048:Health Care Costs; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use; D008297:Male; D008329:Managed Care Programs / Q000191:economics*; D010789:Phototherapy / Q000191:economics / Q000379:methods; D011565:Psoriasis / Q000175:diagnosis / Q000191:economics* / Q000628:therapy; D014481:United States
chemical_list: D001685:Biological Factors; D007166:Immunosuppressive Agents